Hcw Biologics Stock Analysis

HCW Stock Analysis Notes

About 52.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.05. HCW Biologics had not issued any dividends in recent years. HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company was incorporated in 2018 and is headquartered in Miramar, Florida. Hcw Biologics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. To learn more about HCW Biologics call Hing Wong at 954 842 2024 or check out https://www.hcwbiologics.com.

HCW Biologics Investment Alerts

HCW Biologics Upcoming and Recent Events

HCW Largest EPS Surprises

View All Earnings Estimates

HCW Stock Institutional Investors

Note, although HCW Biologics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

HCW Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.95 M.

HCW Profitablity

Management Efficiency

HCW Biologics has return on total asset (ROA) of (0.7009) % which means that it has lost $0.7009 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4432) %, meaning that it created substantial loss on money invested by shareholders. HCW Biologics' management efficiency ratios could be used to measure how well HCW Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.92. In addition to that, Return On Capital Employed is expected to decline to -1.37. At present, HCW Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 45.2 M, whereas Non Current Assets Total are forecasted to decline to about 11.7 M.

Technical Drivers

As of the 26th of November, HCW Biologics retains the market risk adjusted performance of (1.47), and Semi Deviation of 7.39. HCW Biologics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the entity's future prices.

HCW Biologics Price Movement Analysis

HCW Biologics Insider Trading Activities

HCW Biologics Outstanding Bonds

HCW Biologics Predictive Daily Indicators

HCW Biologics Forecast Models

HCW Biologics' time-series forecasting models are one of many HCW Biologics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary HCW Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how HCW Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling HCW shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as HCW Biologics. By using and applying HCW Stock analysis, traders can create a robust methodology for identifying HCW entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. HCW analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. HCW analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

HCW Biologics stock analysis indicators help investors evaluate how HCW Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading HCW Biologics shares will generate the highest return on investment. By understating and applying HCW Biologics stock analysis, traders can identify HCW Biologics position entry and exit signals to maximize returns.

When running HCW Biologics' price analysis, check to measure HCW Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HCW Biologics is operating at the current time. Most of HCW Biologics' value examination focuses on studying past and present price action to predict the probability of HCW Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HCW Biologics' price. Additionally, you may evaluate how the addition of HCW Biologics to your portfolios can decrease your overall portfolio volatility.